Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
AMRX(NASDAQ:AMRX) BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen’s Risperdal Consta®. The product is eligible for 180-day exclusivity under the FDA’s Competitive Generic Therapy (CGT) designation. Product launch is planned for the fourth quarter of 2025.
Amneal Pharma Announces FDA Approval For Prednisolone Acetate Ophthalmic Suspension; Product Launch Planned For Q3 2025
AMRXAmneal Receives FDA Approval For Prednisolone Acetate Ophthalmic Suspension
AMRXGoldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
AMRXGoldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.
Amneal Pharmaceuticals Receives FDA Approval For Brekiya Injection In Acute Treatment Of Migraine And Cluster Headaches In Adults
AMRXAmneal And Apiject Enters Partnership To Expand Sterile And Blow-Fill-Seal Capabilities For Advanced Pharmaceutical Manufacturing In The U.S.
AMRXDrug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed
AMRXAmneal Pharmaceuticals reported first-quarter 2025 adjusted earnings per share of 21 cents, up from 14 cents a year ago.
Amneal Pharmaceuticals Affirms FY2025 Adj EPS Guidance of $0.65-$0.70 vs $0.68 Est; Affirms FY2025 Sales Guidance of $3.00B-$3.10B vs $3.03B Est
AMRXAmneal Pharmaceuticals Q1 Adj. EPS $0.21 Beats $0.15 Estimate, Sales $695.42M Miss $715.49M Estimate
AMRXExamining the Future: Amneal Pharmaceuticals's Earnings Outlook
AMRXAmneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients
AMRXAmneal shares data showing Crexont improves sleep and motor symptoms in Parkinson's patients, with Phase 4 trial underway for further evaluation.
Amneal's CREXONT Shows Sleep Benefits for Parkinson's Patients in Phase 3 Study
AMRXAmneal Announces Expanded Coverage For CREXONT To Enhance Access For Parkinson's Disease Patients In The U.S.; Increases Insurance Coverage To Over 50% Of Covered Lives
AMRXAmneal Pharmaceuticals Unveils BORUZU, First Ready-To-Use Bortezomib Injection For Multiple Myeloma And Mantle Cell Lymphoma
AMRXAmneal And mAbxience Announces FDA Review Acceptance For Two Proposed Denosumab Biosimilars Referencing Prolia And XGEVA. FDA Target Action For the Fourth Quarter of 2025
AMRXBarclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $11
AMRXGeneric Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars
AMRXAmneal Pharmaceuticals' Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue.
Amneal Expects 2025 Revenues Of $3B-$3.1B And Adjusted EPS Of $0.65-$0.70 Versus Consensus Of $2.896B And $0.71, Respectively
AMRXAmneal Pharmaceuticals Q4 2024 Adj EPS $0.12 Misses $0.15 Estimate, Sales $730.52M Beat $707.55M Estimate
AMRXGeneric Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock
AMRXJP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.
JP Morgan Upgrades Amneal Pharmaceuticals to Overweight, Raises Price Target to $12
AMRXAmneal Launches Mesalamine And Receives U.S. FDA Approval For Lenalidomide
AMRXAmneal Pharmaceuticals Expects To Meet Its 2024 Net Revenue, Adjusted EBITDA, And Adjusted EPS Guidance, Exceed Its Operating Cash Flow Guidance - Filing
AMRXAmneal Has Begun Supplying OTC Naloxone Hydrochloride Nasal Spray To U.S. Retail Pharmacies And The State Of California
AMRXRecap: Amneal Pharmaceuticals Q1 Earnings
AMRXAmneal Pharmaceuticals (NYSE:AMRX) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Amneal Pharmaceuticals Maintains FY22 Guidance
AMRXAmneal Pharmaceuticals's Earnings Outlook
AMRXAmneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement.
Analysts estimate that Amneal Pharmaceuticals will report an earnings per share (EPS) of $0.13.
